000111678 001__ 111678
000111678 005__ 20230519145608.0
000111678 0247_ $$2doi$$a10.3390/cancers13143511
000111678 0248_ $$2sideral$$a127858
000111678 037__ $$aART-2021-127858
000111678 041__ $$aeng
000111678 100__ $$aLópez-Vega J.M.
000111678 245__ $$aEarly imaging and molecular changes with neoadjuvant bevacizumab in stage ii/iii breast cancer
000111678 260__ $$c2021
000111678 5060_ $$aAccess copy available to the general public$$fUnrestricted
000111678 5203_ $$aThis prospective, phase II study evaluated novel biomarkers as predictors of response to bevacizumab in patients with breast cancer (BC), using serial imaging methods and gene expression analysis. Patients with primary stage II/III BC received bevacizumab 15 mg/kg (cycle 1; C1), then four cycles of neoadjuvant docetaxel doxorubicin, and bevacizumab every 3 weeks (C2–C5). Tumour proliferation and hypoxic status were evaluated using18F-fluoro-3'-deoxy-3'-L-fluorothymidine (FLT)-and18F-fluoromisonidazole (FMISO)-positron emission tomography (PET) at baseline, and during C1 and C5. Pre-and post-bevacizumab vascular changes were evaluated using dynamic contrastenhanced magnetic resonance imaging (DCE-MRI). Molecular biomarkers were assessed using microarray analysis. A total of 70 patients were assessed for treatment efficacy. Significant decreases from baseline in tumour proliferation (FLT-PET), vascularity, and perfusion (DCE-MRI) were observed during C1 (p = 0.001), independent of tumour subtype. Bevacizumab treatment did not affect hypoxic tumour status (FMISO-PET). Significant changes in the expression of 28 genes were observed after C1. Changes in vascular endothelial growth factor receptor (VEGFR)-2p levels were observed in 65 patients, with a > 20% decrease in VEGFR-2p observed in 13/65. Serial imaging techniques. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
000111678 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000111678 590__ $$a6.575$$b2021
000111678 592__ $$a1.349$$b2021
000111678 594__ $$a5.8$$b2021
000111678 591__ $$aONCOLOGY$$b60 / 245 = 0.245$$c2021$$dQ1$$eT1
000111678 593__ $$aOncology$$c2021$$dQ1
000111678 593__ $$aCancer Research$$c2021$$dQ1
000111678 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000111678 700__ $$aÁlvarez I.
000111678 700__ $$0(orcid)0000-0002-9159-4988$$aAntón Torres, A.$$uUniversidad de Zaragoza
000111678 700__ $$aIllarramendi J.J.
000111678 700__ $$aLlombart A.
000111678 700__ $$aBoni V.
000111678 700__ $$aGarcía-Velloso M.J.
000111678 700__ $$aMartí-Climent J.M.
000111678 700__ $$aPina L.
000111678 700__ $$aGarcía-Foncillas J.
000111678 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000111678 773__ $$g13, 14 (2021), 3511 [17 pp]$$pCancers$$tCancers$$x2072-6694
000111678 8564_ $$s7775115$$uhttps://zaguan.unizar.es/record/111678/files/texto_completo.pdf$$yVersión publicada
000111678 8564_ $$s2886345$$uhttps://zaguan.unizar.es/record/111678/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000111678 909CO $$ooai:zaguan.unizar.es:111678$$particulos$$pdriver
000111678 951__ $$a2023-05-18-16:06:21
000111678 980__ $$aARTICLE